The dihydroergotamine mesylate market is expected to grow at a significant CAGR during the forecast period (2021-2027). Dihydroergotamine is used to treat migraine headaches with or without aura, as well as cluster headache occurrences in the short term. Dihydroergotamine binds to 5-HT1Da and 5-HT1Db receptors with a high affinity. Serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, noradrenaline a2A, a2B, and receptors, and dopamine D2L and D3 receptors all bind to it with great affinity. The agonist action of Dihydroergotamine at 5-HT1D receptors is thought to be responsible for its therapeutic efficacy in migraines.

Growing knowledge of migraine and treatment alternatives, rising R&D spending resulting in a large pipeline of medicines, and rising migraine prevalence along with high unmet requirements are all contributing to the global growth of the dihydroergotamine mesylate market. According to the World Health Organization (WHO) Migraine is the 19th most prevalent cause of disability. Migraine patients take twice as many prescription medicines and visit doctors and emergency rooms twice as often as individuals who do not suffer from the condition. Migraine patients have also spent much more on healthcare. As a result of the rising occurrence of migraines, more therapies are being used to provide relief, which serves to drive the market globally

The US Food and Drug Administration (US FDA) has given Cipla final authorization for its Abbreviated New Drug Application (ANDA) for Dihydroergotamine Mesylate Nasal Spray 4mg/mL, with a Competitive Generic Therapy (CGT) designation in May 2020. Cipla is the first authorized applicant for such a CGT, and as a result, it is eligible for 180 days of CGT exclusivity, which will commence when Cipla's product is commercially marketed.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Type 

o By Application 

• Regions Covered

o North America

o Europe

o Asia-Pacific

o Rest of the world

• Competitive Landscape: Boehringer Ingelheim, Euticals, OLON, TEVA, and AMRI.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Dihydroergotamine Mesylate Market by Segments 

By Type

• Injectable
• Tablets

By Application

• Hypotension
• Headache
• Convulsions
• Calcitonin Gene-related Peptide (CGRP) Antagonist

Global Dihydroergotamine Mesylate Market by Region